Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid Parietaria judaica Immunotherapy for Allergic Rhinoconjunctivitis
NCT00916760Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Feb 2008
- Primary completion
- Feb 2013
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of Depigoid in allergic rhinoconjunctivitis (ARC), sponsored by LETI Pharma. Started Feb 2008; status: completed.
02
Drugs
Depigoid
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00916760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00916760.